Success and failure of vaccines against renin-angiotensin system components (Q34999478)

5 August 2017

1 reference

title

Success and failure of vaccines against renin-angiotensin system components (English)

1 reference

5 August 2017

Morris J Brown

1

1 reference

5 August 2017

language of work or name

English

0 references

publication date

25 August 2009

1 reference

Nature Reviews Cardiology

5 August 2017

published in

1 reference

5 August 2017

volume

6

1 reference

5 August 2017

issue

10

1 reference

5 August 2017

page(s)

639-647

1 reference

Global burden of hypertension: analysis of worldwide data

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Effects of valsartan on mechanical properties of the carotid artery in spontaneously hypertensive rats under high-salt diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Active and passive immunization against angiotensin II in the rat and rabbit. Evidence for a normal regulation of the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

31 March 2020

Essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Continued Improvement in Hypertension Management in England

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Success of surgery for primary aldosteronism judged by residual autonomous aldosterone production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Systolic and diastolic blood pressure control in antihypertensive drug trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Effect of spironolactone on blood pressure in subjects with resistant hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Persistence with treatment in newly treated middle-aged patients with essential hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

31 March 2020

Renin: friend or foe?

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Better blood pressure control: how to combine drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Telmisartan, ramipril, or both in patients at high risk for vascular events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Thrombolytics for PE and right ventricular dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captopril

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

The salt conundrum: a hypothesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Determinants of angiotensin II generation during converting enzyme inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Hyperaldosteronism among black and white subjects with resistant hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Immunologic approaches to blockade of the renin-angiotensin system: a review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Renin-angiotensin vaccine: old story, new project 'efficacy versus safety'.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Active immunization against renin in normotensive marmoset

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Role of angiotensinogen in blood pressure homeostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Hypertension of renal origin: evidence for two different mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Studies on the role of angiotensin in experimental renovascular hypertension: an immunologic approach.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Virus-like particles as a modular system for novel vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

The coming of age of virus-like particle vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.156

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

31 March 2020

1 reference

12 December 2020

Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group

1 reference

12 December 2020

Antirenin in man and animals

1 reference

12 December 2020

Pulmonary angiotensin-converting enzyme. Interspecies homology and inhibition by heterologous antibody in vivo

1 reference

12 December 2020

10.1038/NRCARDIO.2009.156

Identifiers

DOI

1 reference

5 August 2017

1 reference